Biomatrix technology innovator Elutia Inc. (NASDAQ:ELUT) on Friday agreed to divest its SimpliDerm human acellular dermal matrix operations. The buyer, Cellution Biologics Inc., will acquire the asset in a transaction that could be valued at a maximum of $11 million.
This strategic sale allows the medical technology pioneer to refocus its financial and operational efforts toward the development of its upcoming next-generation medical solutions.
Financial Terms And Milestone Payments
According to the specific terms of the acquisition agreement, Elutia is set to secure a guaranteed $8 million in upfront cash at the time the transaction formally closes.
Additionally, the company is eligible to earn up to $3 million in further compensation.
These supplemental payouts are tied to specific technology transfer achievements and commercial milestones, which are expected to be realized over 18 months following the close.
The deal is expected to close during the second half of 2026.
Strategic Pivot To NXT-41x Development
By offloading this specific business unit, the company intends to deliberately channel its internal resources and capital primarily into NXT-41x.
The flagship product is an advanced, antibiotic-eluting biomatrix specifically designed for application in plastic and reconstructive surgical procedures.
The proceeds generated from the SimpliDerm transaction are expected to substantially fortify the firm’s balance sheet, notably achieving this without causing any equity dilution for existing shareholders.
Furthermore, this non-dilutive capital injection will directly support and fund the company’s anticipated commercial rollout of NXT-41x, which is scheduled for 2027.
Targeting Lucrative $1.5 Billion Market
Elutia is aggressively advancing the development of NXT-41x to capture a significant share of the domestic plastic and reconstructive surgery sector.
Management estimates this addressable United States market to be worth approximately $1.5 billion.
ELUT Stock Price Activity: Elutia shares were trading at $0.95 at the time of publication on Friday, according to Benzinga Pro data.
Image via Shutterstock
Login to comment